Innate Pharma announces publication in Science Immunology highlighting innovative next-generation ANKET® IPH6501
Innate Pharma reports Third Quarter 2024 Business Update and Financial Results
Innate Pharma highlights data from its innovative oncology portfolio selected for the SITC Annual Meeting 2024
Innate Pharma announces FDA clearance of the IND for IPH4502, a Nectin-4 ADC to be developed in solid tumors
Innate Pharma reports First Half 2024 Business Update and Financial Results
Monalizumab data from NeoCOAST-2 Phase 2 study in early-stage NSCLC presented at the WCLC 2024
Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial
Innate Pharma presents positive results from TELLOMAK Phase 2 study with lacutamab in mycosis fungoides
Innate Pharma highlights abstracts selected for ASCO 2024 Annual Meeting
Clarification regarding SAR443579 Designation
